Iqvia Holdings Inc (NYSE:IQV) CFO Michael R. Mcdonnell sold 9,500 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $128.35, for a total value of $1,219,325.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NYSE:IQV traded down $1.30 during mid-day trading on Thursday, reaching $121.85. 1,747,600 shares of the stock were exchanged, compared to its average volume of 1,279,150. The firm has a market cap of $24.64 billion, a P/E ratio of 27.73, a PEG ratio of 1.77 and a beta of 0.81. Iqvia Holdings Inc has a 1-year low of $91.57 and a 1-year high of $135.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41.
Iqvia (NYSE:IQV) last released its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. The firm had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. Iqvia’s revenue was up 5.2% on a year-over-year basis. Sell-side analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in IQV. Morgan Stanley boosted its position in shares of Iqvia by 14.6% in the 3rd quarter. Morgan Stanley now owns 1,392,583 shares of the medical research company’s stock valued at $180,673,000 after purchasing an additional 177,638 shares during the period. Legal & General Group Plc boosted its position in shares of Iqvia by 4.0% in the 3rd quarter. Legal & General Group Plc now owns 737,718 shares of the medical research company’s stock valued at $95,711,000 after purchasing an additional 28,123 shares during the period. Standard Life Aberdeen plc boosted its position in shares of Iqvia by 14.2% in the 3rd quarter. Standard Life Aberdeen plc now owns 54,668 shares of the medical research company’s stock valued at $7,094,000 after purchasing an additional 6,817 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of Iqvia by 12,847.9% in the 3rd quarter. Rehmann Capital Advisory Group now owns 64,351 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 63,854 shares during the period. Finally, New Mexico Educational Retirement Board boosted its position in shares of Iqvia by 7.5% in the 3rd quarter. New Mexico Educational Retirement Board now owns 14,400 shares of the medical research company’s stock valued at $1,868,000 after purchasing an additional 1,000 shares during the period. 89.33% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently commented on IQV. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Tuesday, October 23rd. Morgan Stanley raised their price target on Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Monday. Piper Jaffray Companies raised their price target on Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Wells Fargo & Co raised their price target on Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Monday, August 13th. Finally, Barclays raised their price target on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $134.41.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/12/06/iqvia-holdings-inc-iqv-cfo-sells-1219325-00-in-stock.html.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
See Also: Float
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.